News stories about Heat Biologics (NASDAQ:HTBX) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Heat Biologics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.7782091457669 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Heat Biologics (HTBX) Prices for Rights Offering (streetinsider.com)
- Heat Biologics Announces Pricing for Rights Offering to Stockholders and Participating Warrant Holders (finance.yahoo.com)
- Heat Biologics, Inc. (HTBX) Sees Significant Decrease in Short Interest (americanbankingnews.com)
- UPDATE: Heat Biologics to Present at the Upcoming BIO Investor Forum in San Francisco (finance.yahoo.com)
- Before You Buy Heat Biologics Inc’s (HTBX), You Should Consider This (finance.yahoo.com)
Several research analysts have recently issued reports on the company. Griffin Securities assumed coverage on Heat Biologics in a research report on Tuesday, September 12th. They set a “buy” rating and a $2.25 price objective for the company. ValuEngine downgraded Heat Biologics from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Zacks Investment Research downgraded Heat Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Noble Financial reissued a “buy” rating on shares of Heat Biologics in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $2.13.
Shares of Heat Biologics (NASDAQ HTBX) opened at 0.66 on Tuesday. Heat Biologics has a 12-month low of $0.46 and a 12-month high of $3.35. The stock has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.64. The stock’s market capitalization is $23.62 million.
COPYRIGHT VIOLATION WARNING: “Heat Biologics (HTBX) Receives Daily Media Sentiment Score of 0.11” was first reported by BBNS and is owned by of BBNS. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-heat-biologics-htbx-share-price/1698651.html.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with our FREE daily email newsletter.